Group 1 - The core viewpoint of the news highlights the significant stock performance of Charoen Pokphand International (03839.HK), which saw a 21.68% increase in share price, closing at 2.75 HKD per share, with a trading volume of 4.17 million shares and a turnover of 11.09 million HKD [1] - Over the past month, Charoen Pokphand International has achieved a cumulative increase of 20.86%, and a year-to-date increase of 51.68%, outperforming the Hang Seng Index's increase of 17.3% [2] - Financial data shows that as of March 31, 2025, Charoen Pokphand International reported total revenue of 1.185 billion HKD, a year-on-year increase of 201.97%, and a net profit attributable to shareholders of 55.186 million HKD, a year-on-year increase of 677.35% [2] Group 2 - Charoen Pokphand International is a Hong Kong-listed company involved in biochemical and industrial businesses, established as part of the Charoen Pokphand Group since 1995, and is a leading producer of oxytetracycline globally [3] - The company holds a 50% stake in one of China's four major Caterpillar distributors and has been listed on the Hong Kong Stock Exchange since July 2015 [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 3.62 times, with a median of 5.93 times, while Charoen Pokphand International has a P/E ratio of 3.92 times, ranking fourth in the industry [2]
正大企业国际（03839.HK）6月23日收盘上涨21.68%，成交1108.68万港元